MedTrace Logo

XKH001 Injection in Healthy Subjects

NCT05991661 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-05

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) clinical study. The primary objective is to evaluate the safety, tolerability, and PK of multiple SC doses of XKH001 in healthy subjects.

Conditions

Interventions

DRUG

XKH001 Injection

100mg/ml，1ml/vial

DRUG

XKH001 Placebo Injection

1ml/vial

Sponsors & Collaborators

  • Beijing Kanova Biopharmaceutical Co., LTD

    lead INDUSTRY

Principal Investigators

  • Yanhua Ding · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-12
Primary Completion
2024-02-20
Completion
2024-03-29
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05991661 on ClinicalTrials.gov